Publicaciones científicas
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas, Ana Lopez de la Guía, Diego Conde, Isabel Krsnik, Elena Prieto, Rosalía Riaza Grau, Mercedes Gironella, María Jesús Blanchard, Nerea Caminos, Carlos Fernández de Larrea, María Alicia Senin, Fernando Escalante, José Enrique de la Puerta, Eugenio Giménez, Pilar Martínez-Barranco, Juan José Mateos, Luis Felipe Casado, Joan Bladé, Juan José Lahuerta, Javier de la Cruz, Jesús San-Miguel
Abstract
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19.
This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity.
COVID-19 clinical severity was moderate-severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis.
This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.
CITA DEL ARTÍCULO Blood Cancer J. 2020 Oct 19;10(10):103.
doi: 10.1038/s41408-020-00372-5